医学
彭布罗利珠单抗
危险系数
内科学
贝伐单抗
人口
肿瘤科
化疗
外科
无进展生存期
中期分析
置信区间
癌症
胃肠病学
临床试验
免疫疗法
环境卫生
作者
Nicoletta Colombo,Coraline Dubot,Domenica Lorusso,M. Valeria Cáceres,Kosei Hasegawa,Ronnie Shapira‐Frommer,Krishnansu S. Tewari,Pamela Salman,Edwin Hoyos Usta,Eduardo Yañez,Mahmut Gümüş,Mivael Olivera Hurtado de Mendoza,Vanessa Samouëlian,Vincent Castonguay,Arkhipov Alexander,Sarper Toker,Kan Li,Stephen J. O’Keefe,Bradley J. Monk
标识
DOI：10.1056/nejmoa2112435
摘要
Progression-free and overall survival were significantly longer with pembrolizumab than with placebo among patients with persistent, recurrent, or metastatic cervical cancer who were also receiving chemotherapy with or without bevacizumab. (Funded by Merck Sharp and Dohme; KEYNOTE-826 ClinicalTrials.gov number, NCT03635567.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
大力的灵雁
湖工大保卫处
Mic
GingerF
乐空思
畔畔
干净的琦
科研狗
HH
Nexus
Criminology34
侯人雄
plh
小太阳在营业
iNk
AN
凶狠的碧琴
殷勤的紫槐
戒骄戒躁戒熬夜
皖公网安备34019202002308
